Not recruiting
Breast cancer+5
Not recruitingStudy on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse
Registered drugNo placebo
Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse
Registered drugNo placebo
- Disease:Breast cancerBreast cancer metastatic+4
- Substances:Fluoroestradiol F-18
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Fluoroestradiol F-18
- Sponsor:GE Healthcare Limited